Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + remifentanil + esketamine
- Development stage
- Preclinical
- Lead developer
- China-Japan Friendship Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of **propofol**, **remifentanil**, and **esketamine** is a multi-drug regimen used for total intravenous anesthesia (TIVA). Propofol serves as the primary sedative-hypnotic agent, acting as a positive allosteric modulator of the GABA-A receptor. Remifentanil is an ultra-short-acting mu-opioid receptor agonist that provides potent intraoperative analgesia. Esketamine, the S-enantiomer of ketamine, is an NMDA receptor antagonist that contributes both to the anesthetic depth and provides additional analgesia, potentially reducing the required dose of propofol. This specific combination is being investigated by the China-Japan Friendship Hospital to determine optimal Bispectral Index (BIS) ranges and effect-site concentrations for maintaining adequate anesthesia depth during orthopedic procedures such as unilateral knee replacement surgery.
- Other names
- propofol + remifentanil + esketamineTIVA with esketaminepropofol-remifentanil-esketamine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on propofol + remifentanil + esketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + remifentanil + esketamine.